Jay Walker leads ApiJect’s board of directors and the company’s operations, guiding development of ApiJect’s innovative portfolio of drug delivery devices. Mr. Walker and co-founder Marc Koska initially launched ApiJect to address unsafe injections worldwide from reused medical syringes. The single-dose Prefilled ApiJect Injector has the potential to significantly reduce contamination risk and dosing errors. ApiJect has also developed a Temperature Management System enabling BFS manufacturing of a vast array of sterile injectable drugs, including ultra-cold mRNA vaccines. With over $111M in investments from the current round of funding, a team of industry experts, and locations in key regions, ApiJect is committed to making injectable medicines and vaccines safe and accessible to everyone.
The inventor of ApiJect’s breakthrough BFS injection device is Marc Koska, a highly honored “social entrepreneur.” The Prefilled ApiJect Injector is designed for simplicity: Just prior to injection, a fill-finished Blow-Fill-Seal container and intramuscular needle hub are push-twisted together by a healthcare professional. Leading ApiJect R&D, Marc and his team design drug delivery system prototypes that can reliably serve both advanced and developing markets. Through feedback from patients and healthcare providers, Marc has a deep understanding of customers and in building healthcare partnerships. This feedback is the foundation of ApiJect’s Platform to ensure our single-use prefilled injector and future devices meet the needs of all. The ApiJect Platform of drug delivery devices is designed to optimize manufacturing, warehousing, and transportation, using advanced technology, deliver cost efficiencies and accelerating time to market, and most importantly, save lives.
Hanjin In is Chairman and CEO of Tae-Chang Industrial Co., Ltd. of South Korea (T-C), an ApiJect partner as well as a leading global manufacturer of needle products and blood bags. Since 2006 he has served as CEO and Chairman for both TCI and its Kovac-Med company, which manufactures specialty precision injection products. Over the past decade, as a Director of a growing number of TCI affiliates from Indonesia to France and Florida, he has also overseen all company operations worldwide.
Jon Ellenthal has devoted 30 years to starting, building, and leading early-stage companies that seek to change how an established industry does business. Mr. Ellenthal has applied his leadership to high-tech and innovative companies, including technology, health, medical, and pharmaceutical industries. Currently, Jon is President of ApiJect Systems, a public benefit corporation dedicated to making injectable medicines safe and available for everyone, using Blow-Fill-Seal prefilled syringes and specialized needle hubs. At ApiJect, he establishes short- and long-term goals, assesses the direction of ApiJect, and ensures compliance with the company mission. While managing the overall workforce, Mr. Ellenthal leads through the belief that a company is a community by valuing the importance of attracting and retaining highly technical, well-trained people who think outside the box and work as a team.
As Chief Technology Officer, Dr. Weaver is responsible for ApiJect’s development of Blow-Fill-Seal injection devices and production of its initial device, a single-dose prefilled drug delivery system. She leads a dynamic team that aims for innovation in new design and continuous improvement on existing ones.
Peter Stone is a leader in the technology industry, bringing more than 25 years of top-level executive experience in private equity, M&A, and corporate finance, in both private and publicly traded companies both domestically and internationally. At ApiJect, Mr. Stone plays a vital role in the company’s strategic initiatives. As CFO and Secretary, he exercises appropriate fiduciary duties and collaborates with the Board.
Bo Kowalczyk is the Chief Commercial Officer. His expertise and extensive industry knowledge and leadership in the pharmaceutical and medical device industries spans almost 30 years.
Dr. Ed Kelley is the Chief Global Health Officer at ApiJect.
Amy Stewart is a Human Resources executive with 25 years of experience maximizing investment in human capital for organizations, including the past 15 years in the pharmaceutical industry. As a solutions-oriented change leader, Ms. Stewart seeks to balance people strategy with business strategy while demonstrating agility and collaboration throughout organizations. Her strong commitment to DEI (diversity, equity, inclusion) and ESG (environmental social governance) attracts and retains a broad array of talent, strengthening the ApiJect team.
Having been at ApiJect for more than 2 years, Dana Gilland has been an instrumental part of strategic business decision making and the accompanying legal work that goes along with turning our business decisions into actionable agreements and contracts. Among other things, she has played a major role in helping form and continue to develop our most important business relationships and contracts with our partners and external stakeholders.